Ahitagni Biswas

Dr. Ahitagni Biswas

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
ABAhitagni Biswas
Ahitagni Biswas
LKLakhan Kashyap
Lakhan Kashyap
AKAanchal Kakkar
Aanchal Kakkar
CSChitra Sarkar
Chitra Sarkar
PJPramod Kumar Julka
Pramod Kumar Julka
Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant embryonal central nervous system tumor commonly affecting children <3 years of age. It roughly constitutes 1%–2% of all pediatric central nervous system tumors. Recent data show that it is the most common malignant central nervous system tumor in children <6 months of age. Management of this aggressive tumor is associated with a myriad of diagnostic and therapeutic challenges. On the basis of radiology and histopathology alone, distinction of AT/RT from medulloblastoma or primitive neuroectodermal tumor is difficult, and hence this tumor has been commonly misdiagnosed as primitive neuroectodermal tumor for decades. Presence of a bulky heterogeneous solid-cystic mass with readily visible calcification and intratumor hemorrhage, occurring off-midline in children <3 years of age, should alert the radiologist toward the possibility of AT/RT. Presence of rhabdoid cells on histopathology and polyphenotypic immunopositivity for epithelial, mesenchymal, and neuroectodermal markers along with loss of expression of SMARCB1/INI1 or SMARCA4/BRG1 help in establishing a diagnosis of AT/RT. The optimal management comprises maximal safe resection followed by radiation therapy and multiagent intensive systemic chemotherapy. Gross total excision is difficult to achieve in view of the large tumor size and location and young age at presentation. Leptomeningeal spread is noted in 15%–30% of patients, and hence craniospinal irradiation followed by boost to tumor bed is considered standard in children older than 3 years. However, in younger children, craniospinal irradiation may lead to long-term neurocognitive and neuroendocrine sequel, and hence focal radiation therapy may be a pragmatic approach. In this age group, high-dose chemotherapy with autologous stem cell rescue may also be considered to defer radiation therapy, but this approach is also associated with significant treatment-related morbidity and mortality. Novel small molecule inhibitors hold promise in preclinical studies and should be considered in patients with relapsed or refractory tumor.

30 May 2009 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
ABAhitagni Biswas
Ahitagni Biswas
SGShikha Goyal
Shikha Goyal
TPTarun Puri
Tarun Puri
PDPrasenjit Das
Prasenjit Das
CSChitra Sarkar
Chitra Sarkar
GRGoura Kishor Rath
Goura Kishor Rath

3 February 2015 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
ABAhitagni Biswas
Ahitagni Biswas
PJPramod Kumar Julka
Pramod Kumar Julka
SBSameer Bakhshi
Sameer Bakhshi
ASAshish Suri
Ashish Suri
GRGoura Kishor Rath
Goura Kishor Rath

9 April 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
NANarayan Adhikari
Narayan Adhikari
ABAhitagni Biswas
Ahitagni Biswas
AGAjay Gogia
Ajay Gogia
RSRanjit Kumar Sahoo
Ranjit Kumar Sahoo
AGAjay Garg
Ajay Garg
SCSubhash Chander
Subhash Chander

25 February 2009 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
ABAhitagni Biswas
Ahitagni Biswas
TPTarun Puri
Tarun Puri
SGShikha Goyal
Shikha Goyal
RGRuchika Gupta
Ruchika Gupta
MEMuneer Eesa
Muneer Eesa
GRGoura Kishor Rath
Goura Kishor Rath

18 May 2011 in British Journal Of Neurosurgery
Verified
Journal Article
Closed access
PDF file
ABAhitagni Biswas
Ahitagni Biswas
NKNarendra Kumar
Narendra Kumar
PKPankaj Kumar
Pankaj Kumar
RVRakesh Kumar Vasishta
Rakesh Kumar Vasishta
KGKirti Gupta
Kirti Gupta
SMSuresh Narain Mathuriya
Suresh Narain Mathuriya
Aims. We intended to assess the clinicopathological features and treatment outcome in patients of primary gliosarcoma, a rare malignant brain tumour. Materials and methods. Medical records were reviewed and data collected on primary gliosarcoma over an 8-year period (2002–2009) from the departmental archives. Overall survival (OS) was analysed by Kaplan–Meier method. Results. Seventeen patients met the study criterion (male:female = 9:8). Median age and performance status at presentation were 50 years and Karnofsky performance scale (KPS) 70, respectively. Symptoms of raised intracranial tension (in 100%) and motor impairment (in 64.7%) were commonly observed. Tumour location was frontal in four patients, temporal in three, parietal in three, thalamic in one, multilobed in five and multicentric in one. All patients underwent maximal safe surgery (total excision-10, near-total excision-2, subtotal excision and decompression-5). On histopathology, all tumours showed biphasic pattern, glial component positive for glial fibrillary acidic protein (GFAP) and mesenchymal component positive for vimentin and reticulin. Atypia, mitoses, necrosis and endothelial proliferation were identified in the glial component. Post-operative radiotherapy (median dose – 60 Gy/30#/6 weeks) was used in 15 patients (88.2%). Concurrent and adjuvant chemotherapy with temozolomide (TMZ) were used in two patients depending upon affordability. After the completion of treatment, 35.3% patients were asymptomatic, 23.5% had symptomatic improvement, while 41.2% deteriorated. Salvage therapy for local recurrence was used in three patients (temporal lobectomy-1; total excision-1; TMZ+ bevacizumab-1). At last follow-up (FU), eight patients were alive, seven patients dead and two patients lost to FU with symptom. Median overall survival in the evaluable patients (N = 15) was noted to be 8.27 months (6 month survival 60.76%). Conclusions. Primary gliosarcoma, a variant of glioblastoma poses clinical challenge because of rarity, poor prognosis and limited experience. In our centre, principle of therapy is akin to that of glioblastoma – surgery followed by radiation along with concurrent and adjuvant TMZ. However, chemotherapy is often cost-prohibitive in our setting as mirrored by limited use (17.6%). Median survival of only 8.27 months in our series is in concert with the existing survival result of primary gliosarcoma in world literature (6.25–11.5 months).